Pharmaxis Limited
(ASX:PXS) has reported a net loss of $19.5 million, or 13 per cent, in the half year to December 2011.
Revenue from ordinary activities was up 41 per cent, but profit from ordinary activities after tax was down 13 per cent.
Sales in the drug Aridol, Pharmaxis' first commercial product, were up, thanks to US and South Korean customer demand. The drug is a lung function test designed to help doctors diagnose and manage asthma.
Company director Alan Robertson said in the report the decrease in interest income was attributable to the decrease in cash, and cash equivalents, available for investment.
The company won’t pay a dividend.
Pharmaxis reported a net loss of $45.7 million for the six months to June.
